PT - JOURNAL ARTICLE AU - Soni, Apurv AU - Herbert, Carly AU - Lin, Honghuang AU - Yan, Yi AU - Pretz, Caitlin AU - Stamegna, Pamela AU - Wang, Biqi AU - Orwig, Taylor AU - Wright, Colton AU - Tarrant, Seanan AU - Behar, Stephanie AU - Suvarna, Thejas AU - Schrader, Summer AU - Harman, Emma AU - Nowak, Chris AU - Kheterpal, Vik AU - Rao, Lokinendi V AU - Cashman, Lisa AU - Orvek, Elizabeth AU - Ayturk, Didem AU - Gibson, Laura AU - Zai, Adrian AU - Wong, Steven AU - Lazar, Peter AU - Wang, Ziyue AU - Filippaios, Andreas AU - Barton, Bruce AU - Achenbach, Chad J. AU - Murphy, Robert L. AU - Robinson, Matthew AU - Manabe, Yukari C. AU - Pandey, Shishir AU - Colubri, Andres AU - O’Connor, Laurel AU - Lemon, Stephenie C. AU - Fahey, Nisha AU - Luzuriaga, Katherine L AU - Hafer, Nathaniel AU - Roth, Kristian AU - Lowe, Toby AU - Stenzel, Timothy AU - Heetderks, William AU - Broach, John AU - McManus, David D TI - Performance of Rapid Antigen Tests to Detect Symptomatic and Asymptomatic SARS-CoV-2 Infection AID - 10.1101/2022.08.05.22278466 DP - 2023 Jan 01 TA - medRxiv PG - 2022.08.05.22278466 4099 - http://medrxiv.org/content/early/2023/01/23/2022.08.05.22278466.short 4100 - http://medrxiv.org/content/early/2023/01/23/2022.08.05.22278466.full AB - Background Performance of rapid antigen tests for SARS-CoV-2 (Ag-RDT) varies over the course of an infection, and their performance in screening for SARS-CoV-2 is not well established. We aimed to evaluate performance of Ag-RDT for detection of SARS-CoV-2 for symptomatic and asymptomatic participants.Methods Participants >2 years old across the United States enrolled in the study between October 2021 and February 2022. Participants completed Ag-RDT and molecular testing (RT-PCR) for SARS-CoV-2 every 48 hours for 15 days. This analysis was limited to participants who were asymptomatic and tested negative on their first day of study participation. Onset of infection was defined as the day of first positive RT-PCR result. Sensitivity of Ag-RDT was measured based on testing once, twice (after 48-hours), and thrice (after 96 hours). Analysis was repeated for different Days Post Index PCR Positivity (DPIPP) and stratified based on symptom-status.Results In total, 5,609 of 7,361 participants were eligible for this analysis. Among 154 participants who tested positive for SARS-CoV-2, 97 were asymptomatic and 57 had symptoms at infection onset. Serial testing with Ag-RDT twice 48-hours apart resulted in an aggregated sensitivity of 93.4% (95% CI: 89.1-96.1%) among symptomatic participants on DPIPP 0-6. Excluding singleton positives, aggregated sensitivity on DPIPP 0-6 for two-time serial-testing among asymptomatic participants was lower at 62.7% (54.7-70.0%) but improved to 79.0% (71.0-85.3%) with testing three times at 48-hour intervals.Discussion Performance of Ag-RDT was optimized when asymptomatic participants tested three-times at 48-hour intervals and when symptomatic participants tested two-times separated by 48-hours.Competing Interest StatementDDM reports consulting and research grants from Bristol-Myers Squibb and Pfizer, consulting and research support from Fitbit, consulting and research support from Flexcon, research grant from Boehringer Ingelheim, consulting from Avania, non-financial research support from Apple Computer, consulting/other support from Heart Rhythm Society. YCM has received tests from Quanterix, Becton-Dickinson, Ceres, and Hologic for research-related purposes, consults for Abbott on subjects unrelated to SARS-CoV-2, and receives funding support to Johns Hopkins University from miDiagnostics.Funding StatementThis study was funded by the NIH RADx Tech program under 3U54HL143541-02S2 and NIH CTSA grant UL1TR001453. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Institute of Biomedical Imaging and Bioengineering; the National Heart, Lung, and Blood Institute; the National Institutes of Health, or the U.S. Department of Health and Human Services. Salary support from the National Institutes of Health U54HL143541, R01HL141434, R01HL137794, R61HL158541, R01HL137734, U01HL146382 (AS, DDM), U54EB007958-13 (YCM, MLR), AI272201400007C, UM1AI068613 (YCM), U54EB027049 and U54EB027049-02S1 (CJA, RLM).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of WIRB-Copernicus Group (WCG) Institutional Review Board gave ethical approval for this work (20214875).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at https://github.com/soni-lab. https://github.com/soni-lab